Compare VRA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | CRDF |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 114.2M |
| IPO Year | 2010 | 2012 |
| Metric | VRA | CRDF |
|---|---|---|
| Price | $3.37 | $1.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 155.9K | ★ 813.7K |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.47 | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $416,097,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.39 | $1.48 |
| 52 Week High | $4.39 | $4.56 |
| Indicator | VRA | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 54.08 |
| Support Level | $2.35 | $1.51 |
| Resistance Level | $3.80 | $1.83 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 20.09 | 41.03 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.